The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...
1515 Holcombe Boulevard
Houston, TX 77030
Founded in 1989
Intrexon Corporation and ZIOPHARM Oncology, Inc. Enter into License Agreement with The University of Texas M. D. Anderson Cancer Center
Jan 14 15
On January 13, 2015, Intrexon Corporation and ZIOPHARM Oncology Inc. entered into a license agreement, or the License, with The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center, or MD Anderson. Pursuant to the License, the company and ZIOPHARM hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies arising from the laboratory of Laurence J. N. Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson, as well as either co-exclusive or non-exclusive licenses under certain related technologies. In addition, pursuant to the License, MD Anderson has agreed to transfer to ZIOPHARM certain existing research programs described in the License and to grant to the company and ZIOPHARM certain additional technology rights related thereto. In connection with such transfer, the terms of the License also require the company and ZIOPHARM to enter into a research and development agreement with MD Anderson pursuant to which ZIOPHARM will provide funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15 and $20 million per year. The first quarterly payment of $3.75 million due under this arrangement is required to be made by ZIOPHARM within 60 days of the date of the License. The term of the License expires on the last to occur of the expiration of all patents licensed thereunder,or the twentieth anniversary of the date of the License; provided, however, that following the expiration of the term, the company and ZIOPHARM shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the License and subject to a 90 day cure period, MD Anderson will have the right to convert the License into a non-exclusive license if the Company and ZIOPHARM are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the license and subject to a 180 day cure period, MD Anderson will have the right to terminate the license with respect to specific technology funded by the government or subject to a third party contract if the company and ZIOPHARM are not meeting the diligence requirements in such funding agreement or contract, as applicable. Subject to a 30 day cure period, MD Anderson has the right to terminate the License if the Company and ZIOPHARM fail to timely deliver the shares due in consideration for the License. MD Anderson may also terminate the agreement with written notice upon material breach by the company and ZIOPHARM, if such breach has not been cured within 60 days of receiving such notice. In addition, the License will terminate upon the occurrence of certain insolvency events for both the Company and ZIOPHARM and may be terminated by the mutual written agreement of the Company, ZIOPHARM and MD Anderson. On January 9, 2015, in order to induce MD Anderson to enter into the License on an accelerated schedule, the company and ZIOPHARM entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson shall receive consideration of $7.5 million in shares of the company's common stock (or 278,218 shares), and $7.5 million in shares of ZIOPHARM's common stock (or 1,597,602 shares) in each case based on a trailing 20 day volume weighted average of the closing price of the company's and ZIOPHARM's common stock ending on the date prior to the Letter Agreemen.
Oncoceutics and MD Anderson Collaborate to Develop Anti-Cancer Drug
Jan 14 15
Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center have signed a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug. Earlier, preclinical studies of ONC201 have indicated there is merit in further investigation of the drug, which appears to kill cancer cells without harming healthy cells. The Oncoceutics and MD Anderson agreement will result in clinical trials in specific hematologic tumors. This non-traditional alliance between MD Anderson and Oncoceutics aims to enable the clinical development of a transformative medicine for cancer patients. The collaboration is expected to rapidly identify optimal clinical settings for the use of ONC201 in oncology. The strategic agreement also provides for a sharing of risk and potential commercialization of ONC201.
Amgen and The University of Texas MD Anderson Cancer Center Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome
Jan 12 15
Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells. The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells. MDS affects primarily older adults over age 60 and can cause severe anemia, potentially leading to development of acute myelogenous leukemia (AML), a blood cell cancer. The collaboration's innovative approach will draw on the expertise of MD Anderson's Moon Shots Program, which aims to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths. Garcia-Manero leads the MDS/AML Moon Shots Program. The collaborative agreement will allow Amgen and MD Anderson to join forces in a research partnership that aims to take new drug development from "A to Z." The agreement provides for joint development of new agents under pre-determined terms. Amgen retains all commercial rights, while MD Anderson is eligible to receive milestones and royalties upon successful achievement of key objectives. BiTE antibody constructs are recombinant proteins consisting of two separate antibodies held together by a flexible peptide linker or bands of amino acids. The antibodies are designed to function as a link between T cells and cancer cells. One antibody or protein domain binds to the cancer cell's surface, while the other binds to the CD3 on the T cell, resulting in the malignant cell's death. It is thought that BiTE antibody constructs may be engineered to target a range of tumors.